Johnson & Johnson's "New Era" of Growth: Why the Market Underestimates Its Innovative Pipeline

Related Articles

Why is Johnson & Johnson Selling its Orthopedics Unit

7 months ago

Is Johnson & Johnson's $1 Billion Cell Therapy Investment a Game Changer

8 months ago

What's Driving Johnson Controls' Recent Momentum Ahead of Q2 Earnings

6 months ago

Is the Defense Sector Entering a New Era of Growth

7 months ago

Category

You may also like

Stock News•1 months ago

J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead

Johnson & Johnson's pipeline momentum is expected to support growth through 2026 and beyond, driven by new launches, late-stage data, and approvals. The company's diversified portfolio could provide m...

JNJ

Share

Stock News•1 months ago

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future

Johnson & Johnson signaled that new drugs could offset declining sales from patent-protection losses, an 11-word message to shareholders about its future growth strategy.

JNJ

Share

Stock News•2 months ago

Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

Johnson & Johnson raised its full-year revenue and EPS guidance after a blowout quarter, putting the company on track to exceed $100B in annual revenue.

JNJ

Share